RS20050070A - Use of 1kb kinase inhibitors for the treatment of pain - Google Patents

Use of 1kb kinase inhibitors for the treatment of pain

Info

Publication number
RS20050070A
RS20050070A YUP-2005/0070A YUP7005A RS20050070A RS 20050070 A RS20050070 A RS 20050070A YU P7005 A YUP7005 A YU P7005A RS 20050070 A RS20050070 A RS 20050070A
Authority
RS
Serbia
Prior art keywords
pain
treatment
kinase inhibitors
inhibitors
iκb
Prior art date
Application number
YUP-2005/0070A
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans Georg Schaible
Original Assignee
SANOFI-AVENTIS DEUTSCHLAND GnbH.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI-AVENTIS DEUTSCHLAND GnbH., filed Critical SANOFI-AVENTIS DEUTSCHLAND GnbH.,
Publication of RS20050070A publication Critical patent/RS20050070A/sr
Publication of RS51878B publication Critical patent/RS51878B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Inhibitori IκB-kinaze podesni su za proizvodnju lekova za lečenje bolova. Pogodni inhibitori potiču od jedinjenja formule (I) i (Ia).
YU20050070A 2002-08-17 2003-08-05 Primena inhibitora 1kb-kinaze u terapiji bola RS51878B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (2)

Publication Number Publication Date
RS20050070A true RS20050070A (en) 2007-06-04
RS51878B RS51878B (sr) 2012-02-29

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20050070A RS51878B (sr) 2002-08-17 2003-08-05 Primena inhibitora 1kb-kinaze u terapiji bola

Country Status (34)

Country Link
EP (1) EP1531819B1 (sr)
JP (1) JP4504811B2 (sr)
KR (2) KR101119845B1 (sr)
CN (1) CN100398107C (sr)
AR (1) AR043045A1 (sr)
AT (1) ATE418336T1 (sr)
AU (1) AU2003271555B2 (sr)
BR (1) BR0313555A (sr)
CA (1) CA2495455C (sr)
CO (1) CO5690585A2 (sr)
CR (1) CR7716A (sr)
CY (1) CY1108874T1 (sr)
DE (2) DE10237723A1 (sr)
DK (1) DK1531819T3 (sr)
EC (1) ECSP055609A (sr)
ES (1) ES2320118T3 (sr)
HK (1) HK1079426A1 (sr)
HR (1) HRP20050041B1 (sr)
IL (1) IL166780A (sr)
MA (1) MA27334A1 (sr)
MX (1) MXPA05001218A (sr)
MY (1) MY138059A (sr)
NO (1) NO334309B1 (sr)
OA (1) OA12907A (sr)
PL (1) PL212356B1 (sr)
PT (1) PT1531819E (sr)
RS (1) RS51878B (sr)
RU (1) RU2320338C2 (sr)
SI (1) SI1531819T1 (sr)
TN (1) TNSN05044A1 (sr)
TW (1) TWI325782B (sr)
UA (1) UA80837C2 (sr)
WO (1) WO2004022057A1 (sr)
ZA (1) ZA200500323B (sr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2631320C2 (ru) 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN106535899A (zh) * 2014-07-03 2017-03-22 赛诺菲 用于治疗与骨关节炎相关的疼痛的2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑甲酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺
AU2019304216B2 (en) 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50010931D1 (de) * 1999-06-23 2005-09-15 Aventis Pharma Gmbh Substituierte benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
HRP20050041B1 (hr) 2013-07-31
IL166780A (en) 2011-11-30
KR101119845B1 (ko) 2012-02-28
OA12907A (en) 2006-10-13
DE50310980D1 (de) 2009-02-05
JP4504811B2 (ja) 2010-07-14
TW200417370A (en) 2004-09-16
UA80837C2 (uk) 2007-11-12
AU2003271555B2 (en) 2009-03-26
NO334309B1 (no) 2014-02-03
ES2320118T3 (es) 2009-05-19
PL373568A1 (en) 2005-09-05
TNSN05044A1 (en) 2007-05-14
DK1531819T3 (da) 2009-04-20
AR043045A1 (es) 2005-07-13
PT1531819E (pt) 2009-02-18
HK1079426A1 (en) 2006-04-07
ECSP055609A (es) 2005-04-18
MXPA05001218A (es) 2005-05-16
HRP20050041A2 (hr) 2006-04-30
KR20110135428A (ko) 2011-12-16
EP1531819A1 (de) 2005-05-25
AU2003271555A1 (en) 2004-03-29
CA2495455C (en) 2011-01-11
MA27334A1 (fr) 2005-05-02
ZA200500323B (en) 2006-02-22
MY138059A (en) 2009-04-30
RU2005107419A (ru) 2005-08-10
EP1531819B1 (de) 2008-12-24
NO20051339L (no) 2005-05-03
BR0313555A (pt) 2005-07-12
WO2004022057A1 (de) 2004-03-18
RS51878B (sr) 2012-02-29
TWI325782B (en) 2010-06-11
RU2320338C2 (ru) 2008-03-27
CN100398107C (zh) 2008-07-02
SI1531819T1 (sl) 2009-06-30
ATE418336T1 (de) 2009-01-15
KR20050058339A (ko) 2005-06-16
CO5690585A2 (es) 2006-10-31
IL166780A0 (en) 2006-01-15
CR7716A (es) 2008-11-25
CN1674899A (zh) 2005-09-28
CY1108874T1 (el) 2014-07-02
CA2495455A1 (en) 2004-03-18
JP2005539053A (ja) 2005-12-22
DE10237723A1 (de) 2004-07-08
PL212356B1 (pl) 2012-09-28

Similar Documents

Publication Publication Date Title
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
MXPA05013075A (es) Inhibidores de p-38 basados en heterociclo de 5 miembros.
MXPA05013824A (es) Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
TW200510416A (en) P38 inhibitors and methods of use thereof
PL1699800T3 (pl) Bicykliczne heterocykliczne inhibitory kinazy p-38
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
GB0112348D0 (en) Compounds
MY143466A (en) Inhibitors of tyrosine kinases
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
GB0121490D0 (en) Ciompounds
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren